Skip to main content
 

Profile

Wolfgang Baeumer, DVM, Dr.med.vet..habil., Dip. ECVPT

Associate Professor

Contact:

Certifications
Diplomate, European College of Veterinary Pharmacology and Toxicology
Immunology, Pharmacology
My research focus is in the field of immunopharmacology. Currently, three pharmacological targets, the histamine H4 receptor, JAK-STAT-inhibitors and the chemokine thymic stromal lymphopoietin (TSLP) are studied with emphasis on treating allergic skin diseases.

Investigation on the role of histamine H4 receptor as compared to other receptors in allergic inflammation of the skin
This project is funded by the German Research Foundation and is carried out in collaboration with Prof. Dr. Manfred Kietzmann and Dr. Kristine Rossbach from the University of Veterinary Medicine Hannover and Prof. Dr. Ralf Gutzmer and Prof. Dr. Thomas Werfel from the Department of Dermatology, Medical University of Hannover. Dr. Sarah Ehling is working mainly on this project.

Histamine (2 - (4-imidazolyl) ethylamine) is a biogenic amine that is also called a tissue hormone. After the discovery of the histamine H4 receptor (H4R) in 2000, the role of histamine in the formation of the (allergic) inflammation and itching has to be re-visited. The histamine H4 receptor has been functionally characterized in several immune cells involved in allergic diseases. Another important symptom of atopic dermatitis (in dogs as well as in humans) is itch. Itching is mediated via the H4R in mice. Allergen-induced itch can be blocked in mice by the highly selective H4R antagonists. The H4R was recently functionally described in skin innervating neurons by our group.

The janus kinase (JAK) signaling pathway is utilized by several cytokines involved in inflammation (e.g. IL-4 and IL-6) and itch (e.g. IL-31, TSLP). A JAK1 inhibitor has been recently licensed for the treatment of atopic dermatitis in dogs. We are interested in possibly different immune modulatory profiles of JAK inhibitors and their effect on inflammation and itch in acute and chronic models of atopic dermatitis as well as on sensory nerves (DRG) in vitro. This project is mainly carried out by Dr. Tomoki Fukuyama.

Thymic stromal lymphopoietin (TSLP) is an epithelial derived cytokine that plays a central role in the initiation and maintenance of atopic dermatitis. Importantly, very recent studies revealed, that TSLP is also a direct pruritogen and induces itch in mice after injection into the skin. This discovery sheds a totally new light on TSLP as it might be a bridging molecule between inflammation and pruritus, both the pivotal signs of atopic dermatitis. Very little data about TSLP exist in the dog. Joy Ganchingco, DVM, works on the recombinant expression of canine TSLP- and will use it to develop specific antibodies against TSLP. The peptide and antibodies will be used to investigate the role of TSLP in skin tissue samples of atopic dogs as well as to stimulate nerve cells. This study is supported by grant from Morris Animal Foundation.

The working group at the EAVPT congress in Nantes, France, 2015. From left to right: Dr. Sarah Ehling,  Joy Ganchingco, Dr. Wolfgang Baeumer, Dr. Tomoki Fukuyama

The working group at the EAVPT congress in Nantes, France, 2015. From left to right: Dr. Sarah Ehling,
Joy Ganchingco, Dr. Wolfgang Baeumer, Dr. Tomoki Fukuyama

  • Murine and Human Langerhans Cells Express a Functional Histamine H4 Receptor: Modulation of Cell Migration and FunctionGschwandtner M., Rossbach, K., Dijkstra, D., Bäumer, W., Kietzmann, M., Stark, H., Werfel, T., and Gutzmer, G. | Allergy 65, 840-849 (2010)
  • Decreased concentration and enhanced metabolism of sphingosine-1-phosphate in lesional skin of dogs with atopic dermatitis –disturbed sphingosine-1-phosphate homeostasis in atopic dermatitisBäumer, W., Roßbach, K., Mischke, R., Reines I., Langbein-Detsch, I., Lüth, A., Kleuser, B. | J. Invest. Dermatol. 131:266-268 (2011)
  • Lack of preventing effect of systemically and topically administered histamine H1 or H4 receptor antagonists in a dog model of acute atopic dermatitisBäumer W., J Stahl, K Sander, L J. Petersen, J Paps, H Stark, M Kietzmann, T Olivry | Exp. Dermatol. 20(7):577-81 (2011)
  • Histamine H(1), H(3) and H(4) receptors are involved in pruritusRossbach K, Nassenstein C, Gschwandtner M, Schnell D, Sander K, Seifert R, Stark H, Kietzmann M, Bäumer W. | Neuroscience 190: 89-102 (2011)
  • Histamine down-regulates IL-27 production in antigen presenting cellsGschwandtner, M., H. Bunk, B. Köther, R. L. Thurmond, M. Kietzmann, T. Werfel, W. Bäumer, R. Gutzmer | J. Leukoc. Biol. 92, 21-29 (2012)
  • Histamine induces proliferation in keratinocytes from patients with atopic dermatitis through the histamine 4 receptorGlatzer, F., Gschwandtner, M., Ehling, S., Rossbach, K., Janik, K., Klos, A., Bäumer, W., Kietzmann, M., Werfel,T., Gutzmer, R. | J. Allergy Clin Immunol. 132(6):1358-67. (2013)
  • PCR detects bands consistent with the expression of receptors associated with pruritus in canine dorsal root gangliaRossbach, K., Bäumer, W. | Vet. Dermatol. 25(1):9-e4. (2014)
  • Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Anti-Pruritic and Anti-Inflammatory Responses in a Model of Allergic DermatitisFukuyama, T., Ehling, S., Cook, E., Bäumer, W. | J. Pharmacol. Exp. Ther. 354(3):394-405. (2015)
  • Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditionsFukuyama, T., Tschernig, T., Qi, Y., Volmer, D.A., Bäumer, W. | Eur. J. Pharmacol. 764:278-282. (2015)